

Twitter Thread by Syngene Intl

Syngene Intl

@SyngeneIntl



Syngene is delighted to share that we are part of Fortune India's Top 100 Wealth Creators list for 2021.

The criteria involved being a listed company with a 5-year CAGR of 7.5% plus in terms of market cap, revenue & profit (2017-21).

#FortuneIndia #Syngene #FortuneList #CDMO

1/5

A WINNING FORMULA

SYNGENE INTERNATIONAL WAS STARTED BY BIOCON LIMITED IN 1993 TO PROVIDE CONTRACT RESEARCH SERVICES FOR GLOBAL PHARMA COMPANIES. NEARLY THREE DECADES LATER, THE LISTED ENTITY HARBOURS AMBITIONS TO BECOME A GLOBAL SCIENCE COMPANY IN ITS OWN RIGHT.

BY DEBOJYOTI GHOSH

RANK	COMPANY NAME	MARKET CAP*	REVENUE	PROFIT
NEW 2019 69 2021	Syngene International	₹19,675.27 CRORE (15.51%)	₹2,164 CRORE (14.13%)	₹412.10 CRORE (11.34%)

FIGURES IN BRACKETS ARE FIVE-YEAR CAGR IN %. DATA FOR FY20. 'NEW' SIGNIFIES THE COMPANY IS A NEW ENTRANT ON THE 2021 LIST.
*ANNUAL AVERAGE M-CAP AS OF MARCH 31, 2021; SOURCE: PROWESSIQ, CAPITAL INEPLUS

An announcement is imminent. This will be the first approved drug to treat patients with progressive familial intrahepatic cholestasis, or PFIC, a rare inherited condition that causes progressive liver disease until a transplant is required. The global biopharmaceutical company will grab the headlines, but as deserving will be Syngene International Limited, the Bengaluru-based contract research organisation that provided the entire workflow of the testing phase, from pre-clinical supplies to regulatory filings in the U.S. and Europe.

Syngene, which declined to name the client for confidentiality reasons, started in 1993 as a part of biopharma Biocon Limited. It has since grown to a team of about 5,400 employees, roughly 4,700 of whom are scientists who provide end-to-end drug discovery, research, development, and manufacturing services. The company, which was listed on the bourses in 2015, has amassed a clientele of over 400 global companies—ones that typically resist outsourcing critical drug discovery work outside the U.S and Europe.

No wonder Jonathan Hunt, CEO and managing direc-

Those incurring a net loss in any of the 5 fiscals (2016-20) were filtered out. The final 100 were based on firms having revenues of Rs 300 crores or more in FY20.

Key to our success has been our growing clientele who regard us more as a strategic partner with flexibility to work across a spectrum of clients -MNCs to start-ups. We also have a consistent client retention rate of 90%.

#strategicpartnership #clientele #USA #Europe #Japan

3/5

On the range of #scientific work being done at Syngene, our CEO, #Jonathan_Hunt is quoted as saying: "The minute you come into our campus, you can travel the world, scientifically – we do that degree of knowledge-intensive work here".

#Biopharma #CRO #CDMO #CMO #CRDMO

4/5

Our winning formula? Capability to offer integrated services across the #DrugDiscovery, Development, Mfg continuum under one roof; Lean Sigma way of operations; Quality of our work. All this built on the foundation of world-class talent.

#DrugDevelopment #Scientists

5/5